Nordic Nanovector European Patent Granted for Betalutin or Humalutin in Combination With AntiCD20 Antibodies for Treating NHL

Nordic Nanovector: European Patent Granted for Betalutin or Humalutin in Combination With Anti-CD20 Antibodies for Treating NHL

Nordic Nanovector ASA announces that the European Patent Organisation (EPO) has granted the company's European Patent covering the use of Betalutin® or Humalutin® in combination with anti-CD20 antibodies for the treatment of non-Hodgkin's lymphoma (NHL). The same patent has also been issued in Japan...

More From BioPortfolio on "Nordic Nanovector: European Patent Granted for Betalutin or Humalutin in Combination With Anti-CD20 Antibodies for Treating NHL"